Free tool
FAERS Monitor: Retevmo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213246 or its brand name (Retevmo, Selpercatinib). Reports on generic versions are filed under their own applications.
Reports
1,395
Serious
1,084
78% of reports
Hospitalization
443
Death reported
208
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression136
- death114
- diarrhoea72
- hypertension70
- fatigue68
- hypersensitivity65
- rash61
- pyrexia50
- hepatic function abnormal49
- alanine aminotransferase increased42
- aspartate aminotransferase increased42
- off label use41
- nausea40
- ascites39
- dry mouth39
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 82 |
| 2021 | 164 |
| 2022 | 214 |
| 2023 | 217 |
| 2024 | 302 |
| 2025 | 206 |
| 2026 | 210 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,764 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 136 | 20.0 | 17.1 | 2,451 |
| ascitesSignal | 39 | 20.0 | 14.7 | 686 |
| hepatic function abnormalSignal | 49 | 19.8 | 15.1 | 857 |
| aspartate aminotransferase increasedSignal | 42 | 11.9 | 8.9 | 410 |
| alanine aminotransferase increasedSignal | 42 | 10.3 | 7.7 | 345 |
| dry mouthSignal | 39 | 7.3 | 5.3 | 205 |
| hypersensitivitySignal | 65 | 5.3 | 4.2 | 223 |
| hypertensionSignal | 70 | 5.0 | 4.0 | 221 |
| pyrexiaSignal | 50 | 2.2 | 1.7 | 31 |
| rashSignal | 61 | 2.1 | 1.7 | 35 |
| death | 114 | 2.0 | 1.7 | 58 |
| diarrhoea | 72 | 1.7 | 1.3 | 20 |
| fatigue | 68 | 1.3 | 1.0 | 5 |
| nausea | 40 | 0.8 | 0.6 | 3 |
| off label use | 41 | 0.7 | 0.5 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.